Evaluation of the sedative effects of the 3H-dexmedetomdin in the treatment of catheter ablation

Evaluation of the sedative effects of the 3H-dexmedetomdin in the treatment of catheter ablation - Evaluation of the sedative effects of thedexmedetomdin in the treatment of catheter ablation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010022

Enrollment

Registered

2013-02-15

Start date

2013-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

dexmedetomdin using group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Catheter ablation therapy for atrial firillation 2)Age >=20 years, <80 years (Male and Female) 3)A consent form for participating in this study is submitted

Exclusion criteria

Exclusion criteria: 1)Patients with serious disoder in the central nervous system 2)Patients with muscle relaxant drug is required at catheter ablation 3)Having allergy to dexmedetomdin 4)Having allergy to alpha2 antagonist or alpha2 agonist 5)Patients who are pregnant, breastfeeding or intention to becoming pregnant 6)Patients with CHF(>NYHA III) 7)Other patients determined to be inappropriate by physician

Design outcomes

Primary

Measure	Time frame
The time to achieve adequate sedation level was documented	—

Secondary

Measure	Time frame
Heart rate, mean arterial pressure, respiratory rate, oxygen saturation, the degree of pain	—

Countries

Japan

Contacts

Public ContactNaoki Amaya

University of Fukui, Faculty of Medical Sciences Division of cardiovascular Medicine

0776-61-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026